Pfizer launches phase III trial with RSV candidate in September

Following positive data from a phase IIa trial, Pfizer is ready to launch a phase III trial with adults next month with the vaccine candidate rsvpref for treating respiratory syncytial virus (RSV).

Photo: Brian Snyder/Reuters/Ritzau Scanpix

Following positive data from a phase IIa trial, US pharmaceutical company Pfizer is ready to initiate another phase III trial with the vaccine candidate RSVpreF fo treating respiratory syncytial virus (RSV), according to Fiercebiotech.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs